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Abstract
Interest in genomics research in African populations is experiencing exponential growth. This enthusiasm stems in
part from the recognition that the genomic diversity of African populations is a window of opportunity for
innovations in postgenomics medicine, ecology, and evolutionary biology. The recently launched H3Africa
initiative, for example, captures the energy and momentum of this interest. This interdisciplinary socio-technical
analysis highlights the challenges that have beset previous genomics research activities in Africa, and looking
ahead, suggests constructive ways H3Africa and similar large scale science efforts could usefully chart a new era
of genomics and life sciences research in Africa that is locally productive and globally competitive. As inde-
pendent African scholars and social scientists, we propose that any serious global omics science effort, including
H3Africa, aiming to build genomics research capacity and capability in Africa, needs to fund the establishment of
biobanks and the genomic analyses platforms within Africa. Equally they need to prioritize community en-
gagement and bioinformatics capability and the training of African scientists on these platforms. Historically, the
financial, technological, and skills imbalance between Africa and developed countries has created exploitative
frameworks of collaboration where African researchers have become merely facilitators of Western funded and
conceived research agendas involving offshore expatriation of samples. Not surprisingly, very little funding was
allocated to infrastructure and human capital development in the past. Moving forward, capacity building should
materialize throughout the entire knowledge co-production trajectory: idea generation (e.g., brainstorming
workshops for innovative hypotheses development by African scientists), data generation (e.g., genome se-
quencing), and high-throughput data analysis and contextualization. Additionally, building skills for political
science scholarship that questions the unchecked assumptions of the innovation performers be they funders,
scientists, and social scientists, would enable collective innovation that is truly sustainable, ethical, and robust.
Situating OMICS in a Global World
Checking on the premises and delivering
on the promises
Taking a proactive role in the globalization of lifesciences, not to mention global omics systems science
and integrative biology, has been on the strategic develop-
ment agenda of various nations for the past several years. The
development of the life sciences is seen as a way to realize
and deliver innovation in genomics leading to improved
health outcomes. The associated development of a national or
international bioeconomy is also promoted as a way of gen-
erating jobs, employment, and wider economic growth. An
agenda that pushes a developing country towards contribu-
tion to an international bioeconomymay be problematic if we
do not examine the challenges to fair benefit distribution
which arise from being more integrated in the global eco-
nomic system.
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The leaders of prominent science and engineering research
funding agencies from some 50 countries primarily belong-
ing to G-20 and the Organisation for Economic Co-operation
and Development (OECD) recently convened at the U.S.
National Science Foundation in Virginia for the first Global
Merit Review Summit in 2012 (Suresh, 2012). In part, this
reflected efforts to ensure that science can deliver on its
promises in both developed and developing countries, though
the latter binary is increasingly blurred owing to substantial
interdependency between nations, whether classified as de-
veloped or developing. Perhaps it is such pragmatic inter-
dependency and in part motivation to contribute to global
welfare of resource-limited countries through building sci-
ence infrastructure that have led to a number of large-scale
consortia science around the world, the African continent
included. Such scientific consortia often articulate an ethos to
foster open collective innovation (Bessant and Mo¨slein,
2011) and capacity building in advanced technology driven
sciences such as genomics.
Under this overarching context, one of the flagship geno-
mics research projects currently underway in Africa is the
Human Heredity and Health in Africa initiative (H3Africa).
The project was underlined by promissory discourse on how
this and similar global initiatives are going to change the face
of genomics research and more importantly, the health of
Africans (Bishop et al., 2014; H3Africa consortium, 2014).
There is no doubt genomics research on African samples has
the potential to contribute substantially to the improvement
of health and health systems across the world. Human-kind
originated from Africa nearly 200,000 years ago (Hayden,
2013; Ingman et al., 2000) and Africans exhibit the greatest
genetic diversity (Masimirembwa et al., 2014). The H3Africa
project is expected to collect in excess of 50,000 genomics
samples (H3Africa consortium, 2014), representing sub-
stantial progress if we compare to smaller scale projects that
have sequenced 2000 African genomes to date. There is then,
a real and positive potential for massive genomics data
generation.
Thus, funding from the USA NIH (National Institute of
Health) and the UK Wellcome Trust is greatly appreciated.
As independent African researchers in the field, we are also
compelled to articulate the potential caveats and unchecked
assumptions so as to ensure large-scale consortia stay clear of
risks and pitfalls that may potentially fall in blind spots of
decision-makers who conceived them in the field of omics
sciences systems (Dove, 2013). Indeed, such panoptic en-
gagement between H3Africa and other science consortia and
independent field scientists is essential since the findings
from these programs are not only going to benefit Africans
but also the rest of the world, since African genomes are
thought to harbor many clues to disease susceptibility as well
as treatment response (Dandara et al., 2014; H3Africa con-
sortium, 2014; Masimirembwa et al., 2014).
The stated aims of H3Africa go beyond the need to collect
and secure African samples because of their known signifi-
cance, towards building clinical research capabilities in the
African context and fostering collaborations within the Af-
rican scientific community. Delivering on the promissory
discourse, however, depends first on ensuring that benefits
accrue to Africans. This means examining the innovation and
emerging biotechnology governance frameworks in place. It
also requires asking the right questions in global omics and
life sciences and ensuring that African stakeholders are em-
powered to shape the research agenda and also to be able to
continue long after such projects have concluded. To this end,
it is noteworthy that most opinions and reports have been by
persons from within (i.e., beneficiaries to the funding), and
the angle has often been to look at the benefits with lesser
attention to challenges ahead. There is a need for independent
voices working in the genomics field in Africa so both ben-
efits and potential or unintended negatives can be examined
for a truly symmetrical discourse. Second, the promise that
H3Africa will facilitate sustainable science development in
Africa needs to be understood in terms of its contribution to
building capacity (physical resources) as well as capabilities
(human resources). It is hoped that capacity building might
lead to new and extended research programs in other important
areas that are currently lacking on the African continent. For
example, because of population continuity in many parts of
Africa, genomics research on archaeological populations
might assist our understanding of past, present, and future
population dynamics. Other important domains, such as agri-
cultural and ecological research, nutri-metabolomics, tradi-
tional medicine, and Big Data biology will also benefit from
enhanced ‘‘omics’’ and bioinformatics capacity on the conti-
nent (Bondia-Pons et al., 2013; Misra and Panda, 2013; Vivar
et al., 2013; Wang and Chen, 2013).
In the sections that follow, we outline three important and
interrelated factors impacting delivery of the promise of the
H3Africa project; the expansion of governance frameworks,
the improvement of capacities and attendant trust issues, and
the development of human capabilities. Building capacities
and capabilities in the life sciences can lay the foundations of
a bioeconomy, and we discuss in this article the inherent
contradictions in economic systems that strive for sustain-
ability, while at the same time edging towards specialization.
Governance of Knowledge-Based Innovation
and Public Benefit
Governance implies a move away from a governmental
top-down approach towards a more democratic and distrib-
uted approach, a steering role, for ordered rule and collective
action (Dove, 2013). The outputs are no different from those
of government, though the processes essentially vary with an
increased role for nongovernment actors in the policy making
process (Lyall and Tait, 2005). It may be argued that a gov-
ernance approach to the delivery of promise in H3Africa is
important because of the wide range of stakeholders involved
and the range of aims and goals that must be achieved. The
governance approach allows for a more complex set of re-
lationships between these actors to surface, be articulated,
and negotiated. These may be relationships which in the past
have been complicated by issues of trust and power.
It is our contention that the success of H3Africa is im-
portant to all African researchers, those currently holding
H3Africa-funded grants, as well as those who do not have
such grants, because success of this program is likely to lead
to the improvement of our understanding of the role of ge-
netics in disease, and past and present population dynamics.
Importantly, H3Africa aims to establish infrastructure such
as biorepositories to facilitate studies on biodiversity, dis-
ease, and pharmacogenomics of African populations into the
future. The current governance framework, recognizing the
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limited and depletable nature of samples, states that consid-
eration should be given as to when and how these samples are
used and shared and that samples should be used in a manner
that ensures the greatest benefit to the public (H3Africa high
level principles on ethics, governance, and resource sharing).
Importantly, the formation of a biorepository, is the creation
of a commodity which has an implied ‘‘bio-value’’ (Birch
and Tyfield, 2012). Similar to all biorepositories, achieving
benefit to the public with a scarce resource can be problem-
atic especially when considering non-use, secondary uses
of data, patentability of discoveries made on the basis of
H3Africa data, and the criteria used for granting access to
samples (Huzair and Papioannou, 2012; Winickoff, 2007).
Despite substantial scholarship, legislative and regulatory
efforts by national and supra-national bodies, there remain
concerns around informed consent. Informed consent is
complicated in societies who have limited knowledge about
genomics and its applications (Graboyes, 2010). Concern
extends to the validity of individual consent in the face of
increasing knowledge that an individual’s genomics infor-
mation can contribute to information about a community,
tribe, or other subpopulation. Hence the demands by some
African and other developing communities for both indi-
vidual and community consent is also valid (Buseh et al.,
2013; Graboyes, 2010; Mello and Wolf, 2010; Wright et al.,
2013).
Innovation and technology governance frameworks to
steer the conduct of genomics research in most African
countries therefore currently falls short. It should be part of
the remit of H3Africa to lobby governments in and outside
Africa for statutory governance instrument developments to
ensure that democracy in research can be upheld. Without the
input of African stakeholders into the research agenda, there
is a potential risk that the stated aims and goals of Western
funders take priority. Instruments for democratic governance
and regulation are important not only at national level, but
also at the ‘local’ or organizational level to prevent power
differences that could unduly influence the control of re-
sources and enforce inequitable distribution of benefit from
the research. Thus far, the contributions of African gover-
nance initiatives in H3Africa have been mostly eloquent
appeals for funding from the USA and the EU to strengthen
genomics research in Africa. This does not, however, auto-
matically make them equals in the emerging H3Africa ini-
tiative, but mere convincing beneficiaries of the idea.
Arguably, African researchers’ demands for tangible contri-
bution from African organizations and governments could
give the African stakeholders strength of voice in the con-
sortium and in the implementation of the program. What we
argue for is not impossible; indeed, recently, a clinical trial
was successfully completed by a group of mostly African
researchers (Mayosi et al., 2014) working on an identified
African-specific problem under the auspices of IMPI, yet
with very minimal funding.
Building Capacity and Mutual Trust
Fulfilling the promissory rhetoric depends on the capacity
to collect, store, organize, and utilize samples, data, and in-
formation within Africa. Genomics data generation is asso-
ciated with infrastructural requirements such as sustainable
biobanks, genomic characterization platforms, and appro-
priate expertise and training. The establishment of a bior-
epository, if well curated and funded, can be the reservoir of
future projects for training African scientists using emerging
or improved technologies. Alongside enormous potential to
contribute to the improvement of human health, exists a
troubled history of genomics research in Africa and other
resource limited regions around the world (Dandara et al.,
2012; 2014; Gotch and Gilmour, 2007; Graboyes, 2010;
Mello and Wolf, 2010; Wonkam et al., 2011).
With the infusion of research funds to the continent, the
urgency in the collection of biological samples, and antici-
pated quick generation of data, it is inevitable that most if not
all the initial data-generation will be undertaken outside
Africa. However, this should not dampen the enthusiasm to
establish relevant infrastructure in Africa, in the medium to
long-term lifetime of the project.
Continuing to send samples to collaborators outside Africa
without improving capacity to characterize them locally, is
likely to galvanize the existing views of many local ethic
review committees, making them averse to the concept of
global sharing of biological specimens and data, which many
still view as exploitation (Mduluza et al., 2013; Mello and
Wolf, 2010). It is a difficult proposition but this may be
precisely where the H3Africa can show that it is transfor-
mative in its stated vision and objectives. The attempt to
harmonize standards for biobanking is encouraging (Staun-
ton and Moodley, 2013) and hopefully when the time is right,
samples from different collections could be useful in an-
swering pertinent genomic questions that may require much
larger sample sizes.
With the granting of large funds, there is the potential for
mis-management in regions that lack adequate oversight or
are laden with power differences between local and global
researchers and funders. In the last 40 years, we have wit-
nessed around the world multiple cases where large funds
have been mis-managed, which in turn have heavily under-
mined the much needed humanitarian endeavours (Butter-
field, 2004; Halonen et al., 2003; Mosse, 2005). Expenditure
on meetings is often high at initial stages of projects. Meet-
ings for and by consortium members hopefully establish
confidence and trust relationships. Most of the researchers
lack a history of working together and so there should be a
balance between funds used for meetings and funds allocated
to supporting the setting up of infrastructure for genetic data
generation, analysis, and the training of young scientists.
One of the potential problems is the duration of funding for
biobanks. Since they are a special and veritable research re-
source, funding should be assured for the full duration of
H3Africa and beyond. There should already be conversation
at higher levels such as the Africa Union (AU) through their
NEPAD (the New Partnership for Africa’s Development)
program, or at individual country level, to start setting aside
future funding commitments to ensure sustainability of
H3Africa-sponsored biobank funding. Individual govern-
ments particularly those of leading economies such as South
Africa and Nigeria may also avail some funding for this
strategic resource.
In the early days of setting up H3Africa, one of the needs
frequently articulated has been the collection of African ge-
netic/genomic samples, to be characterized by African-based
researchers, with the characterization to be done in Africa.
This is one of the most challenging visions to put into action.
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There seems to be rather little infrastructural development
focus, especially for genetic and genomic data generation
(i.e., genotyping platforms that include sequencing facilities).
If no concrete genetic or genomic characterization platforms
are developed, after the H3Africa funding, African re-
searchers risk returning to the period before this initiative had
commenced, where there was a reliance on the use of Wes-
tern collaborator platforms. Within a bioeconomy, there is a
pressure to specialize in resource or service provision to re-
duce cost and maintain a competitive advantage in a specific
area. This would provide only limited local benefit and work
against sustainable science development. It is therefore in the
interest of African scientists in H3Africa, to push forward a
core inclusive agenda so that such infrastructure spending on
such platforms is realized.
The formation of H3Africa brought excitement and jus-
tified hope especially with respect to the involvement of
Africa-based researchers on decisions concerning how the
samples collected from Africa are going to be utilized (in-
cluding secondary and tertiary usage). However, consider-
ing the troubled collaboration history summarized above,
there has always been an underlying trepidation among
African researchers, both within and outside the H3Africa
consortium, that this could be another potential way to
sanitize the removal of African biological samples in a well-
coordinated manner with the complicity of African-based
researchers, for the benefit of those outside the African
continent.
Indeed, taking into account the history of biological sam-
ple movement in Africa and elsewhere in the developing
world, where there was unregulated and unauthorised re-
cruitment and sampling of populations (Graboyes, 2010), the
H3Africa Communicable and Noncommunicable Diseases
Working Groups produced a White Paper in January 2011
titled ‘‘Harnessing Genomic Technologies Toward Improv-
ing Health in Africa: Opportunities and Challenges’’. The
White Paper boldly stated:
.. the establishment of a viable, productive clinical and
research infrastructure, through combined leveraging of ca-
pacity, expertise, and infrastructure within existing institu-
tions and investing in new centers of excellence. This new
infrastructure will require investment in capacity develop-
ment. (H3Africa White paper, 2011).
In effect, the vision broadly encapsulates resource develop-
ment, infrastructure development and Education and training
(www.h3africa.org).
The White Paper outlined the challenges as well as pos-
sible solutions. Prominent infrastructural resource develop-
ments proposed included setting up of biobanking facilities
(possibly to stem the tide of parachute science where bio-
logical samples were removed from Africa for studies
abroad) and notably:
. provision of technological infrastructure (units/centers of
excellence) for genetic and genomic data generation and
analysis that enables investigators to accomplish clinical
research in the African context and to foster collaborations
within the African scientific community (H3Africa White
paper, 2011).
Being on the African continent and experienced in the social
studies of the global life sciences R&D, we are not fully
convinced that there is sufficient buy-in by H3Africa
researchers to keep their biological samples at the H3Africa
sponsored biobanks. This could partly be due to the difficulty
experienced where ingrained and troubled historical practices
with researchers who have become a conduit for sample
provision to offshore collaborators, are expected to change
overnight in their thinking and personal ethos, and suddenly
start to share and keep samples together. Efforts to build
systems of open innovation or collaborative innovation are
therefore premised on trust relationships. Of note, mutual
trust is built slowly over time rather than overnight. More-
over, collaborations involving North–South partners bring to
this relationship a particular historical dimension that has
been underexplored in studies of innovation.
Generally, capacity building efforts should be considered
throughout the knowledge production chain, from idea gen-
eration, to data generation, to data analysis, interpretation and
knowledge-based innovation and ultimately science-driven
societal development and prosperity. A more integrated ca-
pacity building approach that takes into account the devel-
opment of people (as we discuss in the next section)
alongside the development of physical resources, may help
prevent brain drain and unsustainable capacity building
(Table 1).
Development of Human Capabilities
Underlying both the establishment of a more effective
ethics and governance framework and the unlocking of po-
tential in physical infrastructure is a need to develop human
‘capability’ (which we borrow from Sen’s (1985) people
centered approach in economic development). Since the re-
lease of the White Paper, and the awarding of research grants
totalling nearly $80 million over 5 years via the H3Africa
initiative, the tone of the rhetoric and sentiments among in-
volved researchers seems to have changed. It could be early
days because the immediate issues facing the researchers are
around training African researchers on issues around sample
collection (e.g., administering consent, taking care of ethical
and legal issues, temporary storage, and shipping of sam-
ples). This is already an investment in scientific capability, a
form of brain-gain.
In other words, African researchers should not establish
their role in the bioeconomy merely as sample providers
(providing the rawmaterial for the beginning of a value chain
that ends in the West or richer countries) for which their
epidemiological studies were a reward. The PhDs and Post-
docs arising from H3Africa associated training, should be
recognized as experts in their own right and be encouraged to
make novel and original contributions to the field.
As discussed in the previous section, genomics research
dealing with African populations was happening but mostly
through large exports of biological samples to western
countries that often was lamented by African researchers and
has since created a negative perception for Africans within
the continent and those in the diaspora (Buseh et al., 2013;
Graboyes, 2010), which endures to this date. Any analysis of
large consortia including H3Africa must take into account the
historical legacy and scholarship on globalization in a context
of ‘‘Big Biology’’ and the ways in which historical and global
socio-technical forces might shape innovation trajectories in
data-intensive omics sciences in Africa (Dove, 2013; Rajan,
2006; 2013).
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For example, in the past, prior to H3Africa, the sending of
samples out of the continent was mostly to African re-
searchers based in diaspora or on quasi-collaborations be-
tween African-based researchers and their well-resourced
Western counterparts where power differences in research
resources made such collaborations not equitable. Western
counterparts characterized and analyzed data from these
samples training their own researchers who then often be-
came ‘‘experts’’ on African problems. This bias and inequity
largely side-lined the training of researchers situated in
Africa, in part leading to the dearth of research capability
observed on the African continent. An additional avenue of
sample export from Africa has been and still includes activ-
ities through clinical trials by the pharmaceutical industry,
something that needs due consideration but is beyond the
scope of this commentary and is mentioned for the sake of
completeness (Nienaber, 2011; Pang 2011; Warner et al.,
2011). Thus, consortia such as H3Africa can assist in re-
ducing the brain-drain and possibly turn it into a brain-gain.
Also mentioned previously is the need for a core inclusive
agenda for genomic characterization platforms to be realized
in Africa. The establishment of these platforms will lead to
the training of individuals on the respective techniques for
using and maintaining such infrastructure. There is com-
mendable training in bioinformatics that has been put in
place (Adoga et al., 2014; Bishop et al., 2014). Indeed, this is
one of the current success stories of H3Africa which, as a
potential to revolutionalize genomics research, however, we
hope for more. If the coordination observed in H3Africa in
these early days is anything to go by, this may in some way
lead to improved brain-gain. However, this training will be in
vain if it is only focused on data-analysis without also pro-
moting training in data generation. The impressive focus on
bioinformatics training prepares African scientists to manage
and handle huge amounts of data that are foreseen to be
generated either abroad or from centers to be set-up locally. If
genomics data are not going to be generated in Africa, all the
training that is happening in bioinformatics will not be sus-
tainable, in our personal view, as trainees will most likely
follow where data are being generated, leaving Africa in a
worse-off position.
From the original intention to have samples analyzed in
Africa, which in itself would be the right catalyst for infra-
structural development, the emphasis seems to now being
placed on data generation from anywhere where there are
functioning facilities. As previously mentioned, this is the
scenario that existed before the launch of H3Africa, where
African researchers were mostly collectors of samples (Gotch
and Gilmour, 2007). We cannot afford to return to where we
existed before H3Africa and certainly should not end worse
off as African scientists and society, when the H3Africa
funding stream runs out. Genomics research, if well-estab-
lished, could also place ‘‘omics’’ research at the center of
understanding other important fields such as physical an-
thropology and archaeology.
The Way Forward and Concluding Remarks
Africa has been and will remain an important resource for
genetics research as confirmed by the following statement
taken from the H3Africa White Paper under the title The
Future of H3Africa:
The model proposed for H3Africa seeks to position Africa
not only as a vital resource for genetic and genomic data
collection but also as the recognized scientific hub for the
initiation and full implementation of modern genetic and
genomics research in African populations. The success of
H3Africa depends largely on the provision of adequate re-
sources and infrastructure for African scientists (H3Africa
White Paper, 2011)
We are hopeful that H3Africa concretely transforms the
previous status of Africa as a resource for sample collection
and instead stimulates the evolution of Africa into a veritable
Table 1. Topline Executive Points to Rethink for
Sustainable Scientific Capacity Building in Africa
and Sustainable Innovation for All
 H3Africa and other infrastructure capacity building
efforts for 21st century science and knowledge-based
innovation around the world are valuable initiatives that
can potentially benefit many. Yet the dynamic 21st
century science initiatives demand real-time calibration
including of the efforts for capacity building such as
H3Africa and beyond. Voices and scientific expertise in
Africa ‘‘from the ground up’’ are crucial to build a
sustainable future for Africa and by Africans in the course
of H3Africa and well beyond.
 Any capacity building effort in Africa cannot afford to
overlook the long and painful historical context of
biosample shipments from the continent by researchers
situated elsewhere offshore; this history has to be born in
mind for any biomedical and life sciences consortia to
succeed now and in the future.
 Capacity-building should materialize in the entire
knowledge co-production trajectory from idea generation
(e.g., brainstorming workshops for innovative idea gen-
eration by African scientists) to data generation (e.g.,
genome sequencing) to data analysis, interpretation and
knowledge-based innovation and ultimately science-
driven societal development and prosperity. In the course
of capacity building, subcontracting out or outsourcing
any component of the above scientific knowledge trajec-
tory would lead to many adverse potentials such as brain
drain, unsustainable capacity building that does not stand
the test of time and the local context and the 21st century
science, among others. An integrated capacity building in
the course of H3Africa and other capacity building
initiatives are essential.
 For sustainable capacity building, what is needed, in
addition to ethics and policy, is a critical lens on discourse
and promissory rhetoric that questions the unchecked
assumptions of science, scientists and social scientists
alike; this can be achieved by incorporating a political
science and discourse analysis pillar to collective inno-
vation and capacity building efforts such as H3Africa that
will – at a truly independent arms length – question-the-
questions and the embedded assumptions in science and
knowledge based innovation (De Vries, 2004; Jasanoff,
2003; 2013; Wynne, 2010).
 Finally, it is important to bear in mind opportunity costs
as well: That the end-game in scientific infrastructure
capacity building is not limited to genomics but should
also consider other omics technologies including tech-
nologies that are simple (e.g., frugal innovation) and
importantly, consider innovative ways to link (translate)
discovery science and technology to knowledge-based
innovation and prosperity for all.
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‘‘global innovation hub’’ that attracts new scholars interna-
tionally to its institutions (brain-gain). Building capacity for
genomics data generation and analysis, as espoused in the
H3Africa White Paper vision under infrastructure, is con-
sistent with this forward progressive vision. It is essential that
technology is seen to be transferred and shared in an altruistic
way, especially through long-term commitments to capacity
building and training.
Returning to our view that the right questions need to be
asked, before finding the right answers, we have highlighted a
number of unchecked assumptions (summarized in Table 1),
which if taken into account, might well strategically position
H3Africa and other large-scale life sciences consortia to de-
liver on the promises to improve the health, welfare, and re-
search capacity and capability of Africans. In the absence of
such consideration, we put the current exhaustive investments
in global omics science and otherwise well-argued initiatives
at significant risk. This is a historical responsibility and the
time to act is now while the futures are still in the making.
There is no doubt genomics research onAfrican samples has
the potential to contribute substantially to the improvement of
humanhealththroughouttheworld(Dandaraetal.,2012).Inthis
vein, African researchers must be stake holders, they must be
empowered in theprocess so that longafterH3Africahasended,
good scientific research continues on the basis of the infra-
structure set-up during this well-intended and robust funding
period. Buy-in and ‘‘financial-adoption’’ by African govern-
ments is necessary for sustainability and to ensure continued
strengthening of genomics research on the African continent.
In a recent Science article (H3Africa consortium, 2014),
the consortium lists some of their measures of future success
and we would like to add another to this list: catalysis of long-
term funding to ensure long-term sustainability of established
infrastructure including bio-banks, genomic platforms, and
data analysis training programs. This could be achieved
through funding from international bodies such as NEPAD
and any other international body that can support long-term
sustainability. As we describe above, funding programs should
be accompanied by governance mechanisms to allow partici-
pation of all stakeholders in funding decisions and with long-
term strategies that could ensure the self-funding sustainabil-
ity. This is not only with regard to decisions over infrastructure
investment but also with respect to setting the research agenda
and asking the right questions and ensuring research projects
build African scientific capability. For H3Africa to be sus-
tainable, it should serve as a reference point for future en-
gagements within Africa as well as between Africa and the rest
of the world.
Within continent capacity building gradients, for example,
North–South or East–West Africa, could deter progress and
some mixer function to equitably distribute capacity building
efforts in Africa would be helpful. Interfacing with additional
governance instruments such as Science Peace Corps or
micro-grants or other types of instruments for governance of
capacity building might catalyze the much needed infra-
structural capacity development.
As African life scientists and social science scholars expe-
rienced in the field of science and technology studies (STS),
we write this piece with much hope that in 5–10 years’ time,
we will see genuine capacity built in omics science systems
and begin to see the signs that Africa is becoming an inter-
national innovation hub attracting scholars offshore to the
continent. Yet this vision is not ‘‘automatic’’ and requires us to
be reflexive and consider hitherto unchecked assumptions
some of which are noted in Table 1. In the absence of such
consideration, we might instead see a potential movement of
African researchers to offshore or Western labs in the future
unless the H3Africa and similar large scale life sciences efforts
ensure both training and retention of the current and the next
generation of scientists skilled in the entire knowledge co-
production trajectory from data generation to analysis to in-
novation analysis. We believe H3Africa is an opportunity to
change the past—old sanitized ways of simply sourcing ge-
nomics samples from Africa—and move to a future built by
African scientists and Africans for science that is locally
productive, embedded in the local norms and priorities of the
citizens while being globally competitive. This embodies an
opportunity for building mutual trust, and importantly, the
promises and actions on the ground to overlap in the course of
H3Africa and large-scale life sciences initiatives.
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